{"id":546576,"date":"2026-01-02T11:54:30","date_gmt":"2026-01-02T15:54:30","guid":{"rendered":"https:\/\/www.mdbriefcase.com\/?post_type=blog&p=546576"},"modified":"2026-01-02T11:54:31","modified_gmt":"2026-01-02T15:54:31","slug":"implementing-nk3-antagonists-in-clinical-practice","status":"publish","type":"blog","link":"https:\/\/www.mdbriefcase.com\/fr\/blog\/implementing-nk3-antagonists-in-clinical-practice\/","title":{"rendered":"Implementing NK3 Antagonists in Clinical Practice"},"content":{"rendered":"

Neurokinin 3 (NK3) antagonists are a new class of medications<\/strong> designed to manage vasomotor symptoms (VMS), such as hot flashes and night sweats, associated with menopause. Unlike hormone therapy, NK3 antagonists work by modulating the neurokinin-3 receptors involved in the body\u2019s thermoregulation, offering an alternative for patients who cannot or prefer not to use estrogen-based treatments.<\/p>\n\n\n\n

Why It Matters<\/strong><\/h3>\n\n\n\n

VMS affects up to 80% of women during menopause<\/a> and can significantly impact sleep, mood, and overall quality of life. While hormone therapy remains effective for many, some patients face contraindications such as a history of hormone-sensitive cancers, cardiovascular risk, or personal preference to avoid hormones. NK3 antagonists provide a non-hormonal option to address these symptoms effectively.<\/p>\n\n\n\n

How Clinicians Can Implement Them<\/strong><\/h3>\n\n\n\n

Practical considerations for prescribing NK3 antagonists include:<\/p>\n\n\n\n